S
Shinzoh Kudoh
Researcher at Osaka City University
Publications - 120
Citations - 12333
Shinzoh Kudoh is an academic researcher from Osaka City University. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 33, co-authored 119 publications receiving 11763 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Journal ArticleDOI
Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung Cancer
Kiyoyuki Furuse,Masahiro Fukuoka,Masaaki Kawahara,Hideki Nishikawa,Y. Takada,Shinzoh Kudoh,Nobuyuki Katagami,Yutaka Ariyoshi +7 more
TL;DR: In selected patients with unresectable stage III NSCLC, the concurrent approach yields a significantly increased response rate and enhanced median survival duration when compared with the sequential approach.
Journal ArticleDOI
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Noriyuki Masuda,Masahiro Fukuoka,Yoko Kusunoki,Kaoru Matsui,Nobuhide Takifuji,Shinzoh Kudoh,Shunichi Negoro,Masayuki Nishioka,Kazuhiko Nakagawa,Minoru Takada +9 more
TL;DR: CPT-11 is an active agent against refractory or relapsed SCLC and deserves to be studied more closely as both a single agent and in combination with other drugs to treat patients with SclC.
Journal ArticleDOI
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
Shinzoh Kudoh,Koji Takeda,Kazuhiko Nakagawa,Minoru Takada,Nobuyuki Katakami,Kaoru Matsui,Tetsu Shinkai,Toshiyuki Sawa,Isao Goto,Hiroshi Semba,Takashi Seto,Masahiko Ando,Taroh Satoh,Naruo Yoshimura,Shunichi Negoro,Masahiro Fukuoka +15 more
TL;DR: Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine, and may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.